CSIR NMITLI Programme to conduct “hmAbs” trial to neutrialize COVID-19

CSIR NMITLI Programme to conduct “hmAbs” trial to neutrialize COVID-19

Share This:

CSIR NMITLI Programme to conduct “hmAbs” trial to neutrialize COVID-19

The Council of Scientific and Industrial Research (CSIR) under its New Millennium Indian Technology Leadership Initiative (NMITLI) is to develop human monoclonal antibodies (hmAbs).

These antibodies will neutralise COVID-19 virus in patients.

Notable Points

  • The CSIR on one side is fighting hard against COVID-19 through its own researches.
  • On the other side, it is also working and supporting industries and public sector units that are coming up with solutions to COVID-19.
  • One such initiative is developing “hmAbs”.

About the project

  • The project will generate hmAbs from patients that are in convalescent phase.
  • Convalescent is patients that are recovering from illness.
  • The project also aims to generate hmAbs clones.
  • These clones are expected to neutralize mutated virus.

Israel was first

  • The monoclonal neutralizing antibodies were first developed by Israel.
  • Till now only polyclonal antibodies have been invented.
  • Israel was the first to isolate monoclonal antibodies.

What are monoclonal antibodies?

  • If the antibodies are recovered from a single recovered cell, they are called monoclonal antibodies.
  • On the other hand, if they are recovered from multiple cells, they are called polyclonal antibodies.


  • The NMITLI is the largest PPP (Public-private partnership) model of Research and Development programme in the country.
  • The main aim of the project is to catalyse innovation and technological developments.
  • Previously, fuel cells based on high temperature proton exchange membrane technology was developed under the NMITLI programme.

Leave a Reply

Your email address will not be published. Required fields are marked *

%d bloggers like this: